B
DYN icon

Braidwell’s Dyne Therapeutics DYN Stock Holding History

Braidwell’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Sell
921,598
-760,400
-45% -$14.1M 0.76% 54
2026
Q1 		$30.5M Buy
1,681,998
+203,669
+14% +$3.51M 1.02% 37
2025
Q4 		$28.9M Sell
1,478,329
-1,252,152
-46% -$23.7M 0.92% 42
2025
Q3 		$34.5M Sell
2,730,481
-542,868
-17% -$6.19M 1.02% 31
2025
Q2 		$31.2M Sell
3,273,349
-347,995
-10% -$3.83M 1.07% 32
2025
Q1 		$37.9M Buy
3,621,344
+2,940,162
+432% +$42.1M 1.33% 32
2024
Q4 		$16M Buy
+681,182
New +$20.1M 0.48% 56
2024
Q1 		– Sell
-755,811
Closed -$10.1M – 74
2023
Q4 		$10.1M Sell
755,811
-1,066,161
-59% -$10.4M 0.37% 58
2023
Q3 		$16.3M Buy
1,821,972
+444,100
+32% +$4.78M 0.52% 65
2023
Q2 		$15.5M Hold
1,377,872
– – 0.51% 59
2023
Q1 		$15.9M Buy
1,377,872
+624,727
+83% +$8.11M 0.52% 59
2022
Q4 		$8.73M Buy
+753,145
New +$8.71M 0.29% 76

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Braidwell's DYN Position: Q2 2026 in Review

Braidwell reduced its Dyne Therapeutics (DYN) stake by 45% in Q2 2026, selling an estimated $14.1M and leaving 921,598 shares worth $20.5M. The position accounts for 0.76% of the portfolio, ranked #54.

Braidwell first reported a position in DYN in Q4 2022 and has held it in 12 quarters since. The position peaked at $37.9M in Q1 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Braidwell held 921,598 shares of Dyne Therapeutics worth $20.5M as of Q2 2026.
  • Braidwell sold 760,400 Dyne Therapeutics shares in Q2 2026, an estimated $14.1M.
  • Dyne Therapeutics made up 0.76% of Braidwell's portfolio in Q2 2026, its #54 holding.
  • Braidwell first reported a position in Dyne Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • Braidwell's Dyne Therapeutics position peaked at $37.9M in Q1 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.